Priyanka Singanwad

Ms. Priyanka Singanwad

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
MUMilind Janrao Umekar
Milind Janrao Umekar
MQMohammad Qutub
Mohammad Qutub
PSPriyanka Singanwad
Priyanka Singanwad
Engineered exosomes have emerged as transformative drug carriers, uniquely equipped to overcome biological barriers in central nervous system (CNS) disorders and cancer therapy. These natural extracellular vesicles, derived from cell membranes, offer inherent biocompatibility, low immunogenicity, and the ability to traverse physiological obstacles such as the blood–brain barrier (BBB) and dense tumor stroma. Recent advances in exosome engineering—including surface modification (e.g., ligand conjugation for receptor-mediated targeting) and cargo loading (siRNA, CRISPR-Cas systems, and chemotherapeutics)—have enhanced their precision and therapeutic utility. For CNS delivery, exosomes functionalized with brain-homing peptides (e.g., RVG or TfR ligands) have enabled the efficient transport of neuroprotective agents or gene-editing tools to treat Alzheimer’s disease or glioblastoma. In oncology, engineered exosomes loaded with tumor-suppressive miRNAs or immune checkpoint inhibitors exploit tumor microenvironment (TME) features, such as acidity or enzyme overexpression, for spatially controlled drug release. Furthermore, hybrid exosome–liposome systems and exosome–biomaterial composites are being explored to improve payload capacity and stability. Despite progress, challenges persist in scalable production, batch consistency, and regulatory standardization. This review critically evaluates engineering strategies, preclinical success, and translational hurdles while proposing innovations such as AI-driven exosome design and patient-derived exosome platforms for personalized therapy. By bridging nanotechnology and biomedicine, engineered exosomes can represent a paradigm shift in targeted drug delivery, offering safer and more effective solutions for historically intractable diseases.


1 September 2026 in Journal of Holistic Integrative Pharmacy
Verified
Journal Article
Open access
ATAmol A. Tatode
Amol A. Tatode
SBShrikant Bute
Shrikant Bute
MQMohammad Qutub
Mohammad Qutub
TPTanvi Premchandani
Tanvi Premchandani
JTJayshree Taksande
Jayshree Taksande
PSPriyanka Singanwad
Priyanka Singanwad